Takeda, Zinfandel Launch TOMMORROW Trial to Evaluate Alzheimer's Onset Risk Algorithm, AD-4833 | GenomeWeb

This article has been updated from a previous version to correct the pioglitazone dose to be used in the TOMMORROW trial. It is 0.8 mg/day, not 0.6 mg/day. Originally published Sept. 3.

Takeda Pharmaceutical announced last week the launch of the Phase III TOMMORROW trial, through which the company is hoping to prove the efficacy and safety of low-dose pioglitazone, dubbed AD-4833, in delaying the onset of mild-cognitive decline due to Alzheimer's in individuals at high risk for the illness.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.